Get the Stockscreener App
54.91
4.39%
-2.52
After Hours:
53.52
-1.39
-2.53%
Celcuity Inc stock is traded at $54.91, with a volume of 1.01M.
It is down -4.39% in the last 24 hours and up +9.69% over the past month.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
See More
Previous Close:
$57.43
Open:
$57.33
24h Volume:
1.01M
Relative Volume:
0.85
Market Cap:
$2.33B
Revenue:
-
Net Income/Loss:
$-63.78M
P/E Ratio:
-20.49
EPS:
-2.68
Net Cash Flow:
$-53.91M
1W Performance:
-1.39%
1M Performance:
+9.69%
6M Performance:
+404.69%
1Y Performance:
+274.81%
1-Day Range:
$54.88
$57.67
1-Week Range:
$54.88
$63.06
52-Week Range:
$7.575
$63.06
Celcuity Inc Stock (CELC) Company Profile
Name
Celcuity Inc
Sector
Industry
Phone
763-392-0767
Address
16305 36TH AVENUE N, MINNEAPOLIS, MN
Compare CELC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
54.91 | 2.37B | 0 | -63.78M | -53.91M | -2.68 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Resumed | Stifel | Buy |
| Jul-22-24 | Initiated | Leerink Partners | Outperform |
| Feb-22-24 | Initiated | Stifel | Buy |
| Dec-08-23 | Initiated | H.C. Wainwright | Buy |
| Oct-08-21 | Initiated | Canaccord Genuity | Buy |
| Sep-07-21 | Initiated | Jefferies | Buy |
| Jul-29-21 | Initiated | Cowen | Outperform |
| Jul-27-21 | Initiated | Needham | Buy |
| Jan-28-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-24-20 | Reiterated | H.C. Wainwright | Buy |
| May-11-20 | Resumed | Craig Hallum | Buy |
| Nov-20-18 | Initiated | H.C. Wainwright | Buy |
View All
Celcuity Inc Stock (CELC) Latest News
Celcuity (NASDAQ:CELC) Stock Price Down 6.9%What's Next? - MarketBeat
Celcuity announces upsized loan facility of $500M - MSN
AlphaQuest LLC Cuts Position in Celcuity, Inc. $CELC - MarketBeat
Trexquant Investment LP Increases Stock Position in Celcuity, Inc. $CELC - MarketBeat
Celcuity, Inc. (NASDAQ:CELC) Sees Significant Increase in Short Interest - MarketBeat
Major Investment Alert: Baker Bros. Advisors LP Boosts Stake in Celcuity! - TipRanks
Celcuity (NASDAQ:CELC) Trading Up 11.8%Still a Buy? - MarketBeat
Why Celcuity’s Stock Faces a Downward Trend - TipRanks
Celcuity (CELC) Expands US$500 Million Credit Facility For Enhanced Financial Flexibility - Yahoo Finance
Celcuity Expands Credit Facility to $500 Million - MSN
Celcuity secures $500 million credit facility for cancer drug development By Investing.com - Investing.com Canada
Celcuity secures $500 million credit facility for cancer drug development - Investing.com
Celcuity announces upsized senior secured term loan facility of $500 million with Innovatus Capital Partners and Oxford Finance - MarketScreener
Celcuity Announces Upsized Senior Secured Term Loan - GlobeNewswire
$500 Million Financing: Celcuity Boosts Credit Facility to Support FDA Filing for Cancer Drug Gedatolisib - Stock Titan
Nuveen LLC Invests $704,000 in Celcuity, Inc. $CELC - MarketBeat
Will Celcuity Inc. benefit from green energy policiesJuly 2025 Drop Watch & Free Technical Confirmation Trade Alerts - beatles.ru
Baker BROS. Advisors LP Has $43.05 Million Holdings in Celcuity, Inc. $CELC - MarketBeat
Paloma Partners Management Co Buys New Holdings in Celcuity, Inc. $CELC - MarketBeat
Celcuity Inc. Earnings Call: Clinical Progress and Financial Fortification - MSN
Celcuity, Inc. $CELC Shares Bought by Wellington Management Group LLP - MarketBeat
Celcuity stock hits all-time high at 55.58 USD By Investing.com - Investing.com Canada
Leading vs lagging indicators on Celcuity Inc. performanceRecession Risk & Precise Buy Zone Tips - Newser
News impact scoring models applied to Celcuity Inc.2025 Risk Factors & Accurate Intraday Trade Tips - Newser
Is Celcuity Inc. forming bullish engulfing patternsTrade Ideas & Consistent Growth Equity Picks - خودرو بانک
Should you wait for a breakout in Celcuity Inc.Weekly Market Outlook & Daily Volume Surge Trade Alerts - Newser
Sentiment analysis tools applied to Celcuity Inc.Chart Signals & Verified Short-Term Plans - Newser
Is Celcuity Inc. a potential multi bagger2025 Pullback Review & Long-Term Growth Portfolio Plans - خودرو بانک
Celcuity stock hits all-time high at 55.58 USD - Investing.com
Forecasting Celcuity Inc. price range with options dataMarket Trend Report & High Return Trade Guides - Newser
Can Celcuity Inc. be recession proof2025 Trading Volume Trends & Real-Time Market Sentiment Reports - خودرو بانک
Is this a good reentry point in Celcuity Inc.Portfolio Growth Summary & Community Supported Trade Ideas - Newser
Is Celcuity Inc. meeting your algorithmic filter criteriaJuly 2025 Big Picture & Safe Entry Point Identification - Newser
Does Celcuity Inc. have strong fundamentalsForecast Cut & AI Powered Buy and Sell Recommendations - خودرو بانک
Key metrics from Celcuity Inc.’s quarterly dataCEO Change & Consistent Growth Equity Picks - Newser
How liquid is Celcuity Inc. stockPortfolio Return Summary & Free Fast Entry Momentum Trade Alerts - خودرو بانک
Charles Schwab Investment Management Inc. Has $2.35 Million Stock Position in Celcuity, Inc. $CELC - MarketBeat
Is Celcuity Inc. showing signs of accumulationMarket Trend Review & Safe Capital Preservation Plans - Newser
Will Celcuity Inc. outperform the market in YEARJuly 2025 Breakouts & Growth Focused Stock Reports - خودرو بانک
Will Celcuity Inc. bounce back from current supportCEO Change & Daily Market Momentum Tracking - Newser
Can you recover from losses in Celcuity Inc.Portfolio Return Summary & AI Powered Trade Plan Recommendations - Newser
Using Python tools to backtest Celcuity Inc. strategies2025 Analyst Calls & AI Driven Stock Reports - Newser
Is a relief rally coming for Celcuity Inc. holdersAnalyst Upgrade & Smart Investment Allocation Insights - Newser
How hedge fund analytics apply to Celcuity Inc. stockJuly 2025 Sentiment & Fast Momentum Entry Tips - Newser
Volume spikes in Celcuity Inc. stock – what they meanExit Point & Consistent Return Investment Signals - Newser
Using data tools to time your Celcuity Inc. exitJuly 2025 Intraday Action & AI Enhanced Execution Alerts - Newser
Celcuity (CELC) Is Up 7.2% After FDA Accepts Gedatolisib NDA for Advanced Breast Cancer Approval - simplywall.st
What recovery options are there for Celcuity Inc.Market Growth Review & Community Consensus Trade Signals - Newser
What is the cash position of Celcuity Inc.July 2025 Retail & Weekly Top Gainers Alerts - خودرو بانک
Celcuity Inc Stock (CELC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):